Curr Opin Immunol. 2025 Apr 30;94:102559. doi: 10.1016/j.coi.2025.102559. Online ahead of print.
ABSTRACT
Psoriasis is a common chronic immune-mediated inflammatory skin disease, with its pathogenesis involving genetic susceptibility, abnormal immune responses, and environmental factors. In recent years, targeted immunotherapy has become a prominent treatment approach. Various drugs targeting cytokines, such as interleukin-17, interleukin-23, and tumor necrosis factor-α, have been introduced, effectively alleviating symptoms. However, due to the complex immunopathogenesis of psoriasis and individual patient differences, single-target drugs may not consistently provide comprehensive treatment effects. Therefore, this article suggests that future research should prioritize multitarget combination therapies to enhance efficacy and reduce resistance. Personalized treatment strategies, based on patients’ genetic, immune, and clinical characteristics, should be developed. Investigating new immunomodulatory mechanisms and drugs, as well as combination therapies that integrate targeted drugs with phototherapy or cellular therapy, is also crucial. Additionally, exploring long-term efficacy and resistance mechanisms will help improve treatment outcomes, with the goal of transforming psoriasis treatment.
PMID:40311222 | DOI:10.1016/j.coi.2025.102559